Sai Parenterals Limited

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32, stating that there are no deviations or variations in the utilization of the proceeds of the Initial Public Offer (IPO) during the quarter ended June 30, 2026.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about change in Management, with the Board Meeting approving the re-appointment of Mr. Anil Kumar Karusala as Director and Managing Director, and the appointment of Mr. Kunal Kakumanu as Additional and Executive Director. The meeting also approved the resignation of Ms. Shivali Aggarwal as Company Secretary & Compliance Officer and Mrs. Aruna Karusala as Non-Executive Director. Additionally, the company has announced the acquisition of a greenfield injectables manufacturing plant and an existing R&D facility, and the ratification of the Sai Parenterals Limited Employee Stock Option Plan, 2025.

Sai Parenterals Limited

Sai Parenterals Limited has submitted its un-audited financial results for the quarter ended June 30, 2026, and announced several board decisions, including the re-appointment of directors, acquisition of new facilities, and ratification of employee stock option plans.

Sai Parenterals Limited

Sai Parenterals Limited has scheduled an earnings conference call to discuss its operational and financial performance for the quarter ended June 30, 2026.

Sai Parenterals Limited

Sai Parenterals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended June 30, 2026.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange regarding the outcome of its Board Meeting held on July 06, 2026, where the Board approved the appointment of secretarial auditors, internal auditors, and cost auditors for the company.

Sai Parenterals Limited

Sai Parenterals' Australian subsidiary, Noumed Pharmaceuticals, has renewed its exclusive OTC supply agreement with a leading Australian pharmacy chain for a 7½-year term, valued at AUD 202 million (approximately INR 1300 crores).

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about bagging/receiving of orders/contracts. The company's subsidiary Noumed Pharmaceuticals Pty Limited has entered an OTC medicines supply agreement with Australia's leading pharmacy network valued at AUD 202 Millions (equivalent to INR 1300 crores). The agreement is for a period of 7.5 years with a further option of 3 years extension upon mutual consent.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about the schedule of an Analyst/Institutional Investor meeting to be held on July 2, 2026, in Mumbai. The meeting will be held in-person and will discuss publicly available information.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about the schedule of an Analyst/Institutional Investor meeting to be held on July 2, 2026, in Mumbai. The meeting will be hosted by Choice Equity Broking Private Limited and will discuss publicly available information.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about the schedule of an Analyst/Institutional Investor meeting to be held on July 2, 2026, in a virtual group meeting hosted by Axis Capital.

Sai Parenterals Limited

Sai Parenterals Limited has closed its trading window for insiders due to the declaration of un-audited financial results for the quarter ending 30.06.2026.